摘要
目的探讨肝移植治疗原发性肝癌合并门静脉癌栓的价值。方法收集我院2000年9月至2005年1月进行的27例原发性肝癌合并门静脉癌栓肝移植病例的临床资料并进行分析。结果本组6个月、1年、2年生存率分别为79.2%、57.1%、51.4%,存活时间最长达46个月,6个月、1年和2年的无瘤生存率为58.3%、37.1%及37.1%。结论如果没有肝外远处转移,肝移植治疗原发性肝癌合并门静脉癌栓是一种有效的姑息治疗方式。
Objective To evaluate the clinical effects and application value of Orthotopic liver transplantation（OLT） for primary heaptocellular carcinoma（HCC） with portal vein tumor thrombi（PVTI＇）, Methods Twenty-seven patients who underwent orthotopic liver transplantation from September 2000 to January 2005 were analyzed. All of them had advanced HCC with PVTr. Results The 6-month, l-year and 2-year survival rate were 79.2%,57.1%,51.4% respectively .The 6-month , 1-year and 2-year patients＇ tumor free survival rate were 58.3% , 37.1% and 37.1% respectively. The longest survival time was 46months. Condusion Liver transplantation is an effective and palliative treatment method for the primary heaptocellular carcinoma with portal vein tumor thrombi if no extrahepatic metastasis.
出处
《中国现代医药杂志》
2006年第8期10-12,共3页
Modern Medicine Journal of China
关键词
原发性肝癌
门静脉癌栓
肝移植
Primary heaptocellular carcinoma
Portal vein tumor thrombi
Liver transplantation.
